1
EXHIBIT 99.1
THURSDAY JULY 20, 4:30 PM EASTERN TIME
COMPANY PRESS RELEASE
SOURCE: Molecular Devices Corporation
MOLECULAR DEVICES REPORTS RECORD REVENUES
AND EARNINGS FOR SECOND QUARTER AND FIRST HALF OF 2000
SUNNYVALE, Calif., July 20 /PRNewswire/ -- Molecular Devices Corporation
(Nasdaq: MDCC) today announced record revenues and earnings for the
second quarter and first half of 2000.
Revenues for the second quarter were $20,307,000, higher than any previous
quarter in the Company's history and a 37% increase over sales reported in the
same period last year. Revenues for the first six months of the year were
$37,375,000, or an increase of 32% compared to the same period of 1999.
Operating income increased 38% in the second quarter and first six months of
the year as compared to operating income in the same periods last year
(excluding the effect of a $2,037,000 write-off of acquired in-process research
and development recorded in the second quarter of 1999).
Diluted earnings per share increased to $0.31 and $0.56 for the second quarter
and first six months of 2000, respectively, compared to $0.24 and $0.44
recorded in the same periods last year (excluding the effect of a $2,037,000,
or $0.13 per share net of tax, write-off of acquired in-process research and
development recorded in the second quarter of 1999).
Commenting on the financial results, Joseph D. Keegan, Ph.D., Molecular
Devices' President and Chief Executive Officer, said, "This was the best
quarter in Company history from both a financial and strategic point of view.
Our fluorescence-based screening products, FLIPR384 and SPECTRAmax Gemini XS,
along with our recently introduced SPECTRAmax PLUS384, continued to drive our
top line growth. Strategically, during the quarter we successfully completed a
follow-on equity offering and announced the signing of a definitive merger
agreement with LJL BioSystems, Inc. We believe these two significant
transactions better position the Company to meet our strategic goal of becoming
the leading supplier of drug discovery solutions to the life sciences industry."
Molecular Devices Corporation is a leading developer of high-performance,
bioanalytical measurement systems that accelerate and improve drug discovery
and other life sciences research. The Company's systems enable pharmaceutical
and biotechnology companies to leverage advances in genomics and combinatorial
chemistry by facilitating the high throughput and cost effective
identification and evaluation
1 of 3
2
of drug candidates. The Company's instrument systems are based on its advanced
core technologies which integrate its expertise in engineering, molecular and
cell biology and chemistry and are fundamental tools for drug discovery and
life sciences research.
This press release contains "forward-looking" statements. For this purpose, any
statements contained in this press release that are not statements of
historical fact may be deemed to be forward-looking statements. Words such as
"believes," "anticipates," "plans," "expects," "will," and similar expressions
are intended to identify forward-looking statements. There are a number of
important factors that could cause the results of Molecular Devices Corporation
to differ materially from those indicated by these forward-looking statements,
including, among others, risks detailed from time to time in the Company's SEC
reports, including its Annual Report on Form 10K for the year ended December
31, 1999 and its Registration Statement on Form S-4, as amended, as of July 17,
2000, and definitive proxy statement filed in connection with the proposed
acquisition of LJL BioSystems, Inc.
MOLECULAR DEVICES CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands)
June 30, December 31,
2000 1999
---------- ------------
(unaudited)
ASSETS
Current assets:
Cash and cash equivalents $ 73,392 $ 28,192
Short-term investments 17,591 --
Accounts receivable, net 19,842 17,416
Inventories 9,998 7,918
Deferred tax asset 2,465 2,465
Other current assets 1,229 721
---------- ---------
Total current assets 124,517 56,712
Equipment and leasehold improvements, net 6,332 2,776
Other assets 6,351 5,263
---------- ---------
$ 137,200 $ 64,751
========== =========
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable $ 4,566 $ 2,624
Accrued liabilities 7,356 5,343
---------- ---------
Total current liabilities 11,922 7,967
Stockholders' equity: 125,278 56,784
---------- ---------
$ 137,200 $ 64,751
========== =========
MOLECULAR DEVICES CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share amounts)
(unaudited)
Three Months Ended Six Months Ended,
June 30, June 30,
2000 1999 2000 1999
--------- --------- --------- ---------
TOTAL REVENUES $ 20,307 $ 14,801 $ 37,375 $ 28,308
TOTAL COST OF REVENUES 7,703 5,283 13,953 10,547
--------- --------- --------- ---------
GROSS MARGIN 12,604 9,518 23,422 17,761
--------- --------- --------- ---------
OPERATING EXPENSES:
Research and
development 2,165 1,780 4,052 3,369
Write-off of acquired
3
in-process research
& development -- 2,037 -- 2,037
Selling, general and
administrative 5,601 4,225 10,685 8,091
-------- -------- -------- --------
Total operating expenses 7,766 8,042 14,737 13,497
-------- -------- -------- --------
INCOME FROM OPERATIONS 4,838 1,476 8,685 4,264
Other income, net 736 347 1,123 768
-------- -------- -------- --------
INCOME BEFORE TAXES 5,574 1,823 9,808 5,032
Income tax provision (2,146) (702) (3,776) (1,938)
-------- -------- -------- --------
NET INCOME $ 3,428 $ 1,121 $ 6,032 $ 3,094
======== ======== ======== ========
BASIC NET INCOME PER SHARE $ 0.33 $ 0.12 $ 0.60 $ 0.32
======== ======== ======== ========
DILUTED NET INCOME PER SHARE $ 0.31 $ 0.11 $ 0.56 $ 0.31
======== ======== ======== ========
SHARES USED IN COMPUTING BASIC
NET INCOME PER SHARE 10,344 9,566 10,023 9,549
======== ======== ======== ========
SHARES USED IN COMPUTING
DILUTED NET INCOME PER SHARE 11,118 10,013 10,859 9,990
======== ======== ======== ========
SOURCE: Molecular Devices Corporation